Ponezumab (PF-04360365) is a humanized monoclonal antibody targeting the C-terminus of beta-amyloid 40 (Abeta40). By binding to Abeta40 in the blood, it establishes a peripheral sink effect, thereby promoting the transfer of amyloid proteins from the central nervous system to the periphery and reducing brain plaque burden. It is primarily used for pharmacological research in Alzheimers disease and cerebral amyloid angiopathy.
Purity:
95.00%
CAS Number:
[1178862-65-1]
Target:
Beta Amyloid
* VAT and and shipping costs not included. Errors and price changes excepted
